Thousands sue Johnson & Johnson in UK over cancer claims

Legal action against US healthcare giant Johnson & Johnson got underway in London on Thursday, over claims its talcum powder caused cancer.

Source: Sharecast

A lawsuit was filed at the High Court against J&J and Kenvue UK, a subsidiary of the firm’s former consumer health unit Kenvue, which was spun off in 2023.

It has been filed by more than 3,000 people who allege their ovarian cancer or mesothelioma were caused by using Johnson’s Baby Powder between 1965 and 2023.

Talc is a naturally occurring mined mineral, which the claimants allege contains asbestos.

J&J is already facing 1000s of similar lawsuits in the US. Last week it was ordered to pay $966m to the family of a woman who died from mesothelioma, one of the largest awards against the company to date.

J&J has long denied all claims against it, however, and has successfully appealed a number of rulings.

The firm told Reuters that Kenvue "retained the responsibility and any purported liability for talc-related litigation outside of the US and Canada".

Kenvue - which also owns Tylenol, Listerine and Nicorette, among others - insisted the powder "did not contain asbestos, and does not cause cancer".

It said: "The safety of Johnson’s Baby Powder is backed by years of testing by independent and leading laboratories, universities and health authorities in the UK and around the world.

"The high-quality cosmetic grade talc that was used…was compliant with any required regulatory standards, did not contain asbestos and does not cause cancer."

J&J stopped selling talc-based powder in the US in 2020 and in the UK in 2023, switching instead to a corn starch-based product.

Isin: US4781601046
Exchange: New York Stock Exchange
Sell:
$ 192.67
Buy:
$ 193.07
Change: 1.10 ( 0.57 %)
Date:
Prices delayed by at least 15 minutes

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

Bank of Scotland is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.

Important legal information

Bank of Scotland Share Dealing Service is operated by Halifax Share Dealing Limited. Halifax Share Dealing Limited. Registered in England and Wales No. 3195646. Registered Office: Trinity Road, Halifax, West Yorkshire HX1 2RG. Authorised and regulated by the Financial Conduct Authority, 12 Endeavour Square, London, E20 1JN under number 183332. A Member of the London Stock Exchange and an HM Revenue & Customs Approved ISA Manager.

Logo Allfunds

The information contained within this website is provided by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd unless otherwise stated. The information is not intended to be advice or a recommendation to buy, sell or hold any of the shares, companies or investment vehicles mentioned, nor is it information meant to be a research recommendation. This is a solution powered by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd incorporating their prices, data news, charts, fundamentals and investor tools on this site. Terms and conditions apply. Prices and trades are provided by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd and are delayed by at least 15 minutes.

FE fundinfo Logo

Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.

Refinitiv Logo

© 2025 Refinitiv, an LSEG business. All rights reserved.